Back to Search Start Over

Role of A Novel Angiogenesis FKBPL-CD44 Pathway in Preeclampsia Risk Stratification and Mesenchymal Stem Cell Treatment.

Authors :
Todd N
McNally R
Alqudah A
Jerotic D
Suvakov S
Obradovic D
Hoch D
Hombrebueno JR
Campos GL
Watson CJ
Gojnic-Dugalic M
Simic TP
Krasnodembskaya A
Desoye G
Eastwood K-A
Hunter AJ
Holmes VA
McCance DR
Young IS
Grieve DJ
Kenny LC
Garovic VD
Robson T
McClements L
Todd N
McNally R
Alqudah A
Jerotic D
Suvakov S
Obradovic D
Hoch D
Hombrebueno JR
Campos GL
Watson CJ
Gojnic-Dugalic M
Simic TP
Krasnodembskaya A
Desoye G
Eastwood K-A
Hunter AJ
Holmes VA
McCance DR
Young IS
Grieve DJ
Kenny LC
Garovic VD
Robson T
McClements L
Publication Year :
2021

Abstract

<h4>Context</h4>Preeclampsia is a leading cardiovascular complication in pregnancy lacking effective diagnostic and treatment strategies.<h4>Objective</h4>To investigate the diagnostic and therapeutic target potential of the angiogenesis proteins, FK506-binding protein like (FKBPL) and CD44.<h4>Design and intervention</h4>FKBPL and CD44 plasma concentration or placental expression were determined in women pre- or postdiagnosis of preeclampsia. Trophoblast and endothelial cell function was assessed following mesenchymal stem cell (MSC) treatment and in the context of FKBPL signaling.<h4>Settings and participants</h4>Human samples prediagnosis (15 and 20 weeks of gestation; n ≥ 57), or postdiagnosis (n = 18 for plasma; n = 4 for placenta) of preeclampsia were used to determine FKBPL and CD44 levels, compared to healthy controls. Trophoblast or endothelial cells were exposed to low/high oxygen, and treated with MSC-conditioned media (MSC-CM) or a FKBPL overexpression plasmid.<h4>Main outcome measures</h4>Preeclampsia risk stratification and diagnostic potential of FKBPL and CD44 were investigated. MSC treatment effects and FKBPL-CD44 signaling in trophoblast and endothelial cells were assessed.<h4>Results</h4>The CD44/FKBPL ratio was reduced in placenta and plasma following clinical diagnosis of preeclampsia. At 20 weeks of gestation, a high plasma CD44/FKBPL ratio was independently associated with the 2.3-fold increased risk of preeclampsia (odds ratio = 2.3, 95% confidence interval [CI] 1.03-5.23, P = 0.04). In combination with high mean arterial blood pressure (>82.5 mmHg), the risk further increased to 3.9-fold (95% CI 1.30-11.84, P = 0.016). Both hypoxia and MSC-based therapy inhibited FKBPL-CD44 signaling, enhancing cell angiogenesis.<h4>Conclusions</h4>The FKBPL-CD44 pathway appears to have a central role in the pathogenesis of preeclampsia, showing promising utilities for early diagnostic and therapeutic purposes.

Details

Database :
OAIster
Publication Type :
Electronic Resource
Accession number :
edsoai.on1355963564
Document Type :
Electronic Resource